Toronto – A webinar addressing challenges in the development of stable cell lines for biomanufacturing will be held on March 24, 2026, according to an announcement released today by Xtalks, a life science community platform. The event focuses on optimizing the process of single-cell cloning in Chinese Hamster Ovary (CHO) cells, a critical step in producing protein, cellular, and gene therapies.
The webinar, titled “Evaluating the Impact of Cell Culture Supplements on CHO Clonal Outgrowth Efficiency,” will feature Adam Causer, Global Product Manager for the Solentim Portfolio at Nova Biomedical, and Dorothee Düsterhöft, Associated Scientist at UGA Biopharma. The speakers will present strategies to improve cell survival and expansion during the early stages of clonal development, a phase often hampered by low viability and delays, according to the release.
Single-cell cloning, the process of isolating individual cells to create a homogenous population, is a fundamental component of biomanufacturing. But, the process can be prone to variability, leading to inconsistencies between different cell pools and cloning campaigns. The webinar will address common sources of this variability and explore approaches to mitigate them, with a particular emphasis on the role of cell culture supplements.
Attendees will also receive guidance on transitioning cloning workflows toward chemically defined environments, a requirement for regulatory compliance. The presentation will draw on data from multiple independent single-cell cloning studies, highlighting how optimized supplementation strategies can support robust clonal outgrowth and reduce inconsistencies. The speakers will focus on factors driving reproducible single-cell outgrowth in CHO cell line development (CLD) platforms and how workflow choices impact performance and consistency.
According to a separate announcement from Cytena, a company specializing in single-cell isolation technologies, key metrics for robust CLD processes include single-cell dispensing efficiency, clonal derivation assurance, and cloning efficiency. UP.SIGHT™ 2nd Gen technology is highlighted as a tool for optimizing these metrics. STEMCELL Technologies also emphasizes the importance of monoclonality and robust cell expansion in mammalian cell line development, offering semi-solid cloning methods like ClonaCell™ as a means to achieve these goals.
The Xtalks webinar is scheduled for 8 a.m. EDT (1 p.m. CET/EU-Central) on March 24, 2026. Registration information is available at http://www.novabiomedical.com/.
